药物降眼压对高近疑青光眼患者影响的随机对照试验方案
GSHM研究是一项单中心开放标签随机对照试验,计划纳入264例35至65岁新诊断的高近疑青光眼患者,随机分入降眼压药物组或无治疗对照组,随访36个月,主要结局为视野检测的疑青光眼进展发生率,旨在评估药物降眼压对该人群的影响。
要点
- 高近疑青光眼患者是否及何时使用降眼压药物尚不明确。
- 该试验计划纳入264例35至65岁患者,1:1随机分组,随访36个月。
- 主要结局为36个月内视野检测的疑青光眼进展发生率。
核心结论
- GSHM研究是首个探讨药物降眼压对高近疑青光眼患者影响的随机对照试验,结果将对临床管理有启示。
研究设计与样本
- GSHM研究为开放标签、单中心随机对照试验,计划于2020至2021年在中山大学中山眼科中心招募264例35至65岁新诊断高近疑青光眼患者。
- 参与者按1:1随机分为干预组(接受降眼压药物)和对照组(无治疗随访36个月或至终点),每例仅一只眼入组,双眼合格时选视野较差眼。
关键数值与推荐
- 主要结局为36个月内通过视野检测的疑青光眼进展发生率。
- 次要结局包括视神经乳头形态(含视网膜神经纤维层)改变、视网膜神经节细胞-内丛状层丢失、近视性黄斑病变进展、视功能丧失及生活质量变化的发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, whether and when intraocular pressure (IOP)-lowering medication should be used in glaucoma suspects with high myopia (GSHM) remains unknown. Glaucoma suspects are visual field (VF) defects that cannot be explained by myopic macular changes or other retinal and neurologic conditions. Glaucoma progression is defined by VF deterioration. Here we describe the rationale, design, and methodology of a randomized controlled trial (RCT) designed to evaluate the effects of medically lowering IOP in GSHM (GSHM study). METHODS: The GSHM study is an open-label, single-center, RCT for GSHM. Overall, 264 newly diagnosed participants, aged 35 to 65 years, will be recruited at the Zhongshan Ophthalmic Center, Sun Yat-sen University, between 2020 and 2021. Participants will be randomly divided into two arms at a 1:1 ratio. Participants in the intervention arm will receive IOP-lowering medication, while participants in the control arm will be followed up without treatment for 36 months or until they reach the end point. Only one eye per participant will be eligible for the study. If both eyes are eligible, the eye with the worse VF will be recruited. The primary outcome is the incidence of glaucoma suspect progression by VF testing over 36 months. The secondary outcomes include the incidence of changes in the optic nerve head morphology including the retinal nerve fiber layer, and retinal ganglion cell-inner plexiform layer loss, progression of myopic maculopathy, visual function loss, and change in the quality of life. Statistical analyses will include baseline characteristics comparison between the intervention and control groups using a two-sample t-test and Wilcoxon rank sum test; generalized linear models with Poisson regression for the primary outcome; Kaplan-Meier curve and log-rank test for the incidence of the secondary outcome; and longitudinal analyses to assess trends in outcomes across time. DISCUSSION: To the best of our knowledge, the GSHM study is the first RCT to investigate the impact of medically lowering IOP in GSHM. The results will have implications for the clinical management of GSHM. TRIAL REGISTRATION: ClinicalTrials.gov NCT04296916 . Registered on 4 March 2020.
引用
- Lin FB, Da Chen S, Song YH, et al. Effect of medically lowering intraocular pressure in glaucoma suspects with high myopia (GSHM study): study protocol for a randomized controlled trial. Trials. 2020. PMID: 32993769. doi:10.1186/s13063-020-04748-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。